Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jul 28, 2025
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding Trontinemab (Presentation of Latest Data in Alzheimer’s Disease at AAIC)
TOKYO, July 28, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release today, including the latest data of trontinemab for Alzheimer’s disease, presented at the Alzheimer's Association International Conference (AAIC) 2025.
Please refer to the link below for details of the Roche’s media release:
Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC
https://www.roche.com/media/releases/med-cor-2025-07-28
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp